April 14, 2010 (FinancialWire) — Access Pharmaceuticals, Inc. (OTCBB: ACCP) said it has completed its first commercial scale North American production run of MuGard, its treatment for certain side effects of chemotherapy and radiation treatment, at Accupac, Inc. manufacturing facilities outside Philadelphia.

Access said it plans to use the initial batches of MuGard for pre-launch key institution evaluations, preliminary stock for select wholesalers and specialty distributors, and additional post-approval studies to be conducted in the U.S. pursuant to guidelines and protocols that are currently being developed. Accupac manufactures, fills and packages a range of consumer commodity, over-the-counter and prescription products for pharmaceutical and consumer products companies. Access said that MuGard is FDA-approved for the management of oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.  

MuGard has been launched in the UK, Germany, Italy, Sweden, Norway and Greece through Access’ European partner, SpePharm.

The company added that JCOM, Inc., its Korean licensee for both MuGard and ProLindac, has received approval from the Korean Food and Drug Administration for MuGard and plans a commercial launch later this year.

MuGard is a novel mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [mlstnsrcgntn]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.